NYRADA INC (ASX:NYR) 56 For the options granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows: Grant date Assumed expiry date Share price at grant date Exercise price Expected volatility Dividend yield Riskfree interest rate Fair value at grant date Valuation model 03/10/2023 03/10/2027 $0.0200 Note1 70.00% - 4.05% $0.0090 Monte Carlo 03/10/2023 03/10/2028 $0.0200 Note1 70.00% - 4.05% $0.0091 Monte Carlo 03/10/2023 03/10/2029 $0.0200 Note1 70.00% - 4.05% $0.0094 Monte Carlo 06/03/2024 30/06/2024 $0.0650 $0.1350 226.21% - 4.35% $0.0610 BlackScholes 1 The exercise price is higher of: ● 100% of the Fair Market Value (as defined in the Company's Stock Incentive Plan) of the Shares on the date that Option is granted; and ● an amount equal to 120% of the volume-weighted average price of the CDIs for the period of 10 trading days immediately prior to the date on which the Option vests. 18. Loss per share 2024 2023 $ $ Loss after income tax attributable to the owners of Nyrada Inc. (1,391,309) (7,781,692) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 163,006,508 156,008,700 Weighted average number of ordinary shares used in calculating diluted earnings per share 163,006,508 156,008,700 Cents Cents Basic loss per share (0.85) (4.99) Diluted loss per share (0.85) (4.99) There are 31,200,000 options which have vested and are considered to be dilutive. The options are not included as the Consolidated Entity is loss-making, so incorporating in the impacts of contingent equity is anti-dilutive.

RkJQdWJsaXNoZXIy MjE2NDg3